Prometic Presents New PBI-4050 Clinical Data From Ongoing Alstr�m Syndrome Phase 2 Trial

New clinical data presented at the International Liver CongressTM 2018; PBI-4050 decreased insulin resistance in the liver Fat biopsies further demonstrate PBI-4050 clinical activity; Clinical activity measured in the heart, liver, kidney and fat tissue in patients treated with PBI-4050 over an average of 52 weeks.


Read all

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.